Department of Clinical Laboratory Sciences, The University of Texas Medical Branch, Galveston, TX (Bergbower and Rajendran); Department of Life Sciences, Illinois Eastern Community Colleges, Olney Central College, Olney, IL (Bergbower).
Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston, Texas (Saad); Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Inova Fairfax Hospital, Falls Church, VA (Saad).
Am J Obstet Gynecol MFM. 2024 Nov;6(11):101516. doi: 10.1016/j.ajogmf.2024.101516. Epub 2024 Oct 5.
Asymptomatic bacteriuria affects 2% to 15% of pregnant women, with 20% to 40% developing symptoms later. Symptomatic urinary tract infections are more common in pregnancy, with a prevalence of 33%, posing risks, such as preterm delivery, low birthweight, and maternal pyelonephritis. The gold standard for urinary tract infection detection is a urine culture, but point-of-care urinalysis dipsticks are frequently performed as screens during regular obstetrical visits. Leukocyte esterase has been used to justify the treatment of asymptomatic bacteriuria, even with low sensitivity and specificity. Confirmatory tests are crucial for avoiding false positives and ensuring optimal outcomes. Current guidelines for urinalysis dipstick interpretation and the decision to treat asymptomatic bacteriuria in pregnancy are limited. It remains unclear whether an evidence-based algorithm can improve test utilization, diagnosis, and treatment decisions for asymptomatic bacteriuria in pregnancy.
The primary objective of our study was to develop, implement, and evaluate an evidence-based algorithm to guide urinalysis interpretation, culture, diagnosis, and antibiotic stewardship of asymptomatic bacteriuria in pregnant patients during routine obstetric visits.
The project involves both retrospective and quasi-experimental prospective medical record reviews of pregnant patients aged ≥18 years, beyond 20 weeks of gestation, from routine obstetrical visits with urinalysis dipstick tests. A doctorate in clinical laboratory sciences student developed an educational algorithm to guide urinalysis dipstick interpretation, culturing necessity, and treatment decisions based on evidence-based practice. Our study considered patient records from February 1, 2022, to February 28, 2022, as retrospective (prealgorithm implementation) data and January 24, 2023, to February 22, 2023, as prospective (postalgorithm implementation) data. Data collected from the electronic medical record included deidentified patient information, urinalysis results, culture dates and outcomes, antibiotic prescriptions, urinary tract infection or asymptomatic bacteriuria diagnoses, provider details, adverse pregnancy outcomes, and demographics. Data analysis using SPSS (version 29; SPSS IBM, Armonk, NY) involved chi-square tests, likelihood ratios, and effect size calculations, with P values of <.05 considered statistically significant.
This study examined a total of 1176 patient records. Preimplementation data included 440 records, of which 224 were abnormal urinalyses and 216 were normal urinalyses. Postimplementation data included 736 records, of which 255 were abnormal urinalyses and 481 were normal urinalysis. The patient demographics predominantly featured White individuals (87%), with a median maternal age of 27 years and a gestational age of 32 weeks. Our preimplementation analyses revealed significant associations of algorithm deviations with both culture utilization (P<.001) and antibiotic stewardship (P<.001). However, no significant association was observed between algorithm deviations and adverse patient outcomes. Culture underutilization decreased significantly from 43.0% (189/440) before implementation to 29.5% (217/736) after implementation (P<.001). The overall reduction in asymptomatic bacteriuria prevalence from 16.3% (8/49) to 6.7% (10/67) suggests a decrease of nearly 60.0%. In addition, antibiotic overprescription decreased significantly from 1.6% (4/258) before implementation to 0.8% (4/522) after implementation (P=.003), with a reduction from 7.1% (3/42) to 2.4% (1/41) among abnormal urinalyses.
Our findings show a strong alignment between the use of the algorithm and subsequent clinical decisions, underscoring its potential to enhance patient care and management in obstetrical settings. Adherence to the algorithm was higher among providers displaying prudent antibiotic use.
无症状菌尿影响 2%至 15%的孕妇,其中 20%至 40%的孕妇随后会出现症状。妊娠时更常见的是有症状的尿路感染,患病率为 33%,会带来早产、低出生体重和母体肾盂肾炎等风险。尿路感染检测的金标准是尿液培养,但在常规产科就诊期间,经常使用即时尿液分析试条作为筛查。白细胞酯酶已被用于证明无症状菌尿的治疗合理性,尽管其敏感性和特异性均不高。确认性试验对于避免假阳性和确保最佳结果至关重要。目前的尿液分析试条解读指南以及妊娠无症状菌尿治疗决策的依据有限。尚不清楚是否可以使用基于证据的算法来改善妊娠无症状菌尿的检测利用、诊断和治疗决策。
我们的主要研究目标是制定、实施和评估一种基于证据的算法,以指导妊娠期间常规产科就诊时的尿液分析解读、培养、诊断和无症状菌尿的抗生素管理。
该项目包括对年龄≥18 岁、妊娠 20 周以上的孕妇的病历进行回顾性和准实验性前瞻性医学记录回顾。一名临床实验室科学博士学生开发了一种教育算法,根据循证实践指导尿液分析试条解读、培养必要性和治疗决策。我们的研究将 2022 年 2 月 1 日至 2 月 28 日的患者记录视为回顾性(算法实施前)数据,将 2023 年 1 月 24 日至 2 月 22 日的患者记录视为前瞻性(算法实施后)数据。从电子病历中收集的信息包括患者的匿名信息、尿液分析结果、培养日期和结果、抗生素处方、尿路感染或无症状菌尿诊断、提供者详情、不良妊娠结局和人口统计学信息。使用 SPSS(版本 29;SPSS IBM,Armonk,NY)进行数据分析,涉及卡方检验、似然比和效应量计算,P 值<.05 被认为具有统计学意义。
本研究共检查了 1176 份患者记录。实施前的数据包括 440 份记录,其中 224 份尿液分析异常,216 份尿液分析正常。实施后的数据包括 736 份记录,其中 255 份尿液分析异常,481 份尿液分析正常。患者的人口统计学特征主要为白人(87%),中位产妇年龄为 27 岁,妊娠周数为 32 周。我们的实施前分析显示,算法偏差与培养利用(P<.001)和抗生素管理(P<.001)显著相关。然而,算法偏差与患者不良结局之间没有显著关联。培养的利用率显著降低,从实施前的 43.0%(189/440)降至实施后的 29.5%(217/736)(P<.001)。无症状菌尿的总体患病率从 16.3%(8/49)降至 6.7%(10/67),降幅接近 60.0%。此外,抗生素的过度处方也显著减少,从实施前的 1.6%(4/258)降至实施后的 0.8%(4/522)(P=.003),异常尿液分析的处方减少从 7.1%(3/42)降至 2.4%(1/41)。
我们的研究结果表明,使用算法与随后的临床决策之间具有很强的一致性,这突显了其在改善产科环境下患者护理和管理方面的潜力。在抗生素使用谨慎的医生中,对算法的依从性更高。